Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:ARZ NYSE:ATC CVE:PA CVE:SCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARZAralez PharmaceuticalsC$0.00C$0.29▼C$3.72C$28.89MN/A79,103 shs274,400 shsATCAtotech$22.71$21.22$18.06▼$25.94$4.42B0.631.09 million shsN/APAPalaminaC$0.12C$0.11C$0.09▼C$0.29C$7.45M2.3841,219 shs57,500 shsSCASavary GoldC$0.12-4.2%C$0.12C$0.04▼C$0.13C$29.40MN/A830,838 shs204,500 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARZAralez Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ATCAtotech0.00%0.00%0.00%0.00%0.00%PAPalamina0.00%0.00%+9.52%+21.05%-28.13%SCASavary Gold0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATCAtotechN/AN/AN/AN/AN/AN/AN/AN/APAPalaminaN/AN/AN/AN/AN/AN/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARZAralez Pharmaceuticals 0.00N/AN/AN/AATCAtotech 0.00N/AN/AN/APAPalamina 0.00N/AN/AN/ASCASavary Gold 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AATCAtotech$1.50B2.95$1.15 per share19.72$4.24 per share5.36PAPalaminaC$0.0018,040,525,445,629,800,000.00C$0.01 per share14.17C$0.01 per share7.73SCASavary GoldN/AN/AC$0.01 per share14.38C$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARZAralez PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AATCAtotech$7.50M$0.6137.23∞N/A8.14%20.32%5.25%N/APAPalamina-C$1.78M-C$0.03N/A∞N/A-429,842,450,360,536,000,000.00%-92.87%-87.90%N/ASCASavary GoldN/A-C$0.00N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARZAralez PharmaceuticalsN/AN/AN/AN/AN/AATCAtotechN/AN/AN/AN/AN/APAPalaminaN/AN/AN/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARZAralez PharmaceuticalsN/AN/AN/AATCAtotech1.891.901.45PAPalaminaN/A2.141.30SCASavary GoldN/A10.0610.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARZAralez PharmaceuticalsN/AATCAtotech94.57%PAPalaminaN/ASCASavary GoldN/AInsider OwnershipCompanyInsider OwnershipARZAralez PharmaceuticalsN/AATCAtotech49.90%PAPalamina24.12%SCASavary GoldN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARZAralez Pharmaceuticals4,50067.19 millionN/ANot OptionableATCAtotech4,033194.66 million97.53 millionNot OptionablePAPalaminaN/A64.81 millionN/ANot OptionableSCASavary Gold1,228255.63 millionN/ANot OptionablePA, SCA, ARZ, and ATC HeadlinesRecent News About These CompaniesSpinnaker SCA Acquires AccelogixFebruary 25, 2023 | benzinga.comMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonPalantir’s Revenue Surge to $1B: Growth vs. ValuationBy Chris Markoch | July 9, 2025View Palantir’s Revenue Surge to $1B: Growth vs. ValuationD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?Rocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackJoby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?By Jeffrey Neal Johnson | July 14, 2025View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?PA, SCA, ARZ, and ATC Company DescriptionsAralez Pharmaceuticals TSE:ARZAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.Atotech NYSE:ATCAtotech Limited, a chemicals technology company, provides specialty electroplating and surface finishing solutions worldwide. The company operates through two segments, Electronics (EL) and General Metal Finishing (GMF). The EL segment manufactures and supplies chemistry, production equipment, software, and services to the electronics industry, which include printed circuit board manufacturers, package substrate makers, and semiconductor companies. Its products and technologies serve the principal electronics end-markets, including communication, computer, automotive, industrial, medical, aerospace, and military industries. The GMF segment provides chemistry, production technology, and services to the surface finishing industries in various areas of application. Its products and technologies serve the primary surface finishing end-markets comprising the automotive, consumer electronics, construction, sanitary, white goods, and oil and gas industries. The company also offers on-site support and training services. Atotech Limited was founded in 1851 and is headquartered in Berlin, Germany.Palamina CVE:PAC$0.12 0.00 (0.00%) As of 08/1/2025 02:00 PM EasternPalamina Corp. engages in the exploration of mineral deposits in Peru and Mexico. It explores for gold, copper, and silver deposits. The company owns interests in the Usicayos, Panorama, Galena, Bendi, Cori, Yin Inca, Gaban, Yang, and Tinka projects located in Peru. Palamina Corp. was incorporated in 2015 and is headquartered in Toronto, Canada.Savary Gold CVE:SCAC$0.12 -0.01 (-4.17%) As of 05/2/2019Savary Gold Corp. engages in the exploration and evaluation of gold properties in West Africa. Its principal project is the Karankasso project that consists of five exploration licenses covering a total area of 688 square kilometers located in the Houndé Gold Belt in Burkina Faso. The company was formerly known as Savary Capital Corp. and changed its name to Savary Gold Corp. in September 2012. Savary Gold Corp. was incorporated in 2008 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
